Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Cytoplasmic isoleucyl tRNA synthetase as an attractive multistage antimalarial drug target

Science Translational Medicine(2023)10.1126/scitranslmed.adc9249Source: DataRank Database

Cytoplasmic isoleucyl tRNA synthetase as an attractive multistage antimalarial drug target is a research paper published in Science Translational Medicine (2023). On theSindex it has a DataRank of 0. It has been cited 27 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access27 citations

Download PDF

Cite:

Linked data & code

uniprot pdb

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (10 grants)OA: greenTopics (48)IDs (PubMed, PMC)Annotations (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (27)

Francisco M. Guerra ORCID,Matthew Abraham ORCID,Kuo‐Sen Huang,Frances Rocamora ORCID,Haoshuang Zhao ORCID

Live enrichment

PubMed:36888694 PMC:PMC10286833

NIGMS NIH HHS

Grant: T32 GM008666

Wellcome Trust

Grant: 206194/Z/17/Z

NIAID NIH HHS

Grant: R01 AI152533

NIAID NIH HHS

Grant: T32 AI007036

National Institutes of Health

Grant: 5T32GM008666-17

Training Program in Basic and Clinical Genetics

Wellcome Trust

Grant: 206194

Wellcome Trust Sanger Institute - generic account for deposition of all core- funded research papers.

National Institutes of Health

Grant: 5R01AI152533-04

Discovery of long-acting, chemoprotective antimalarial compounds

National Institutes of Health

Grant: 5T32AI007036-19

RESEARCH IN INFECTIOUS DISEASES

Wellcome Trust

green

repositoryhttps://escholarship.org/content/qt4zc8t0pc/qt4zc8t0pc.pdf?t=s9o87m

publisherhttps://www.science.org/doi/pdf/10.1126/scitranslmed.adc9249

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC10286833/pdf/nihms-1895173.pdf

https://doi.org/10.1126/scitranslmed.adc9249

https://pubmed.ncbi.nlm.nih.gov/36888694

Fields of Study

03 medical and health sciences0303 health sciencesHumansAntimalarialsIsoleucine-tRNA LigasePlasmodium falciparumMalaria, FalciparumMalariaDrug Resistance

MeSH Terms

HumansPlasmodium falciparumMalariaMalaria, FalciparumIsoleucine-tRNA LigaseAntimalarialsDrug Resistance

Keywords

FalciparumIsoleucine-tRNA Ligase570Clinical SciencesPlasmodium falciparumMedical biotechnologyDrug Resistance610Medical and Health SciencesAntimalarialsRare Diseases/dk/atira/pure/subjectarea/asjc/2700/2700BiodefenseGenetics2.2 Factors relating to the physical environmentHumansname=General MedicineMalaria, FalciparumBiomedical and Clinical SciencesBiological SciencesMalariaVector-Borne DiseasesOrphan DrugEmerging Infectious DiseasesInfectious DiseasesGood Health and Well BeingMedical Microbiology5.1 PharmaceuticalsAntimicrobial ResistanceInfectionBiomedical engineeringBiotechnology